International Clinical Trial: Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus

Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07136389) titled 'Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus' on Aug. 8.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Biocad

Condition: Systemic Lupus Erthematosus

Intervention: Drug: BCD-256 Drug: BCD-256 Drug: BCD-256 Drug: Divozilimab

Recruitment Status: Recruiting

Phase: Phase 1

Date of First Enrollment: March 27, 2025

Target Sample Size: 135

Countries of Recruitment: Russian Federation

To know more, visit ht...